{"id":416,"date":"2025-11-09T09:00:00","date_gmt":"2025-11-09T09:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=416"},"modified":"2025-11-10T08:23:12","modified_gmt":"2025-11-10T08:23:12","slug":"technology-collaboration-sanegenebio-and-lilly-enters-a-1-2-billion-usd-collaboration-on-rnai-research-for-metabolic-disease-targets","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/416.html","title":{"rendered":"[Technology Collaboration] SanegeneBio and Lilly Enters a 1.2 billion USD Collaboration on RNAi Research for Metabolic Disease Targets"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Announced Date: 2025-11-08 (November 08, 2025)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensor: SanegeneBio (China)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Licensee: Eli Lilly\u00a0\uff08US\uff09<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Scope of Collaboration:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">RNAi research for metabolic disease targets<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio&#8217;s proprietary tissue selective delivery technology, LEAD\u2122 (Ligand and\u00a0Enhancer\u00a0Assisted\u00a0Delivery).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SanegeneBio will be responsible for discovery and identification of the optimized LEAD\u2122-based RNAi molecule for each program, while Lilly will be responsible for the subsequent IND-enabling studies, clinical development and commercialization.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Deal Detail:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SanegeneBio will receive an upfront payment and equity investment and will be eligible to receive near-term milestone payments. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">SanegeneBio will also be eligible to receive up to $1.2 billion in discovery, development, regulatory, and commercial milestone payments, as well as tiered royalties on future product sales.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Link:&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.prnewswire.com\/news-releases\/sanegenebio-announces-rnai-licensing-and-research-collaboration-with-lilly-302609299.html\">SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly (prnewswire.com)<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Note:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Chinese Name of SanegeneBio, \u5723\u56e0\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-11-08 (November 08, 2025) Licensor: SanegeneBio (China) Licensee: Eli Lilly\u00a0\uff08US\uff09 . Scope of Collaboration: &hellip; <a title=\"[Technology Collaboration] SanegeneBio and Lilly Enters a 1.2 billion USD Collaboration on RNAi Research for Metabolic Disease Targets\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/416.html\"><span class=\"screen-reader-text\">[Technology Collaboration] SanegeneBio and Lilly Enters a 1.2 billion USD Collaboration on RNAi Research for Metabolic Disease Targets<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-416","post","type-post","status-publish","format-standard","hentry","category-china-tech-corp"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=416"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/416\/revisions"}],"predecessor-version":[{"id":417,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/416\/revisions\/417"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}